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A B S T R A C T
Background
Osteoarthritis is a chronic joint disease that involves degeneration of articular cartilage. Pre-clinical data suggest that doxycycline might
act as a disease-modifying agent for the treatment of osteoarthritis, with the potential to slow cartilage degeneration. This is an update
of a Cochrane review first published in 2009.
Objectives
To examine the effects of doxycycline compared with placebo or no intervention on pain and function in people with osteoarthritis of
the hip or knee.
Search methods
We searched CENTRAL (The Cochrane Library 2008, issue 3), MEDLINE, EMBASE and CINAHL up to 28 July 2008, with an
update performed at 16 March 2012. In addition, we checked conference proceedings, reference lists, and contacted authors.
Selection criteria
We included studies if they were randomised or quasi-randomised controlled trials that compared doxycycline at any dosage and any
formulation with placebo or no intervention in people with osteoarthritis of the knee or hip.
Data collection and analysis
We extracted data in duplicate. We contacted investigators to obtain missing outcome information. We calculated differences in means
at follow-up between experimental and control groups for continuous outcomes and risk ratios (RR) for binary outcomes.
Main results
We identified one additional trial (232 participants) and included two trials (663 participants) in this update. The methodological
quality and the quality of reporting were considered moderate. At end of treatment, clinical outcomes were similar between the two
treatment groups, with an effect size of -0.05 (95% confidence interval (CI) -0.22 to 0.13), corresponding to a difference in pain
scores between doxycycline and control of -0.1 cm (95% CI -0.6 to 0.3 cm) on a 10-cm visual analogue scale, or 32% versus 29%
improvement from baseline (difference 3%; 95% CI -5% to 10%). The effect size for function was -0.07 (95% CI -0.25 to 0.10),
corresponding to a difference between doxycycline and control of -0.2 (95% CI -0.5 to 0.2) on the Western Ontario and McMaster
Universities Arthritis Index (WOMAC) disability subscale with a range of 0 to 10, or 24% versus 21% improvement (difference 3%;
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95% CI -3% to 10%). The difference in changes in minimum joint space narrowing assessed in one trial was in favour of doxycycline
(-0.15 mm; 95% CI -0.28 to -0.02 mm), which corresponds to a small effect size of -0.23 standard deviation units (95% CI -0.44 to -
0.02). More participants withdrew from the doxycycline group compared with placebo due to adverse events (RR 2.28; 95% CI 1.06
to 4.90). There was no evidence that participants in the doxycycline group experienced more serious adverse events than those in the
placebo group, but the estimate was imprecise (RR 1.07; 95% CI 0.68 to 1.68).
Authors’ conclusions
In this update, the strength of evidence for effectiveness outcomes was improved from low to moderate and we confirmed that the
symptomatic benefit of doxycycline isminimal to non-existent, while the small benefit in terms of joint space narrowing is of questionable
clinical relevance and outweighed by safety problems. The CIs of the summary estimates now exclude any clinically relevant difference
in improvement of symptoms and the small benefit in terms of joint space narrowing does not outweigh the harms.
P L A I N L A N G U A G E S U M M A R Y
Doxycycline for osteoarthritis
This summary of a Cochrane review presents what we know from research about the effect of doxycycline on osteoarthritis. After
searching for all relevant studies, they found two studies with 663 people.
The review shows that in people with osteoarthritis:
- doxycycline will not result in clinically important improvement of joint pain or physical function, while the small benefit in terms of
joint space narrowing is of questionable clinical relevance;
- doxycycline probably causes side effects. We often do not have precise information about side effects and complications. This is
particularly true for rare but serious side effects.
What is osteoarthritis and what is doxycycline?
Osteoarthritis is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try and repair the
damage. However, instead of making things better the bone grows abnormally and makes things worse. For example, the bone can
become misshapen and make the joint painful and unstable. This can affect your physical function or ability to use your knee.
It has been claimed that doxycycline, a type of antibiotic, might stop the process of damage to the joints. It is taken in pill form.
Best estimate of what happens to people with osteoarthritis who take doxycycline:
Pain
- The effect of doxycycline in pain symptoms is not clinically important.
- People who took doxycycline rated improvement in their pain to be about 1.9 on a scale of 0 (no pain) to 10 (extreme pain) after 18
months.
- People who took a placebo rated improvement in their pain to be about 1.8 on a scale of 0 (no pain) to 10 (extreme pain) after 18
months.
Another way of saying this is:
- 33 people out of 100 who use doxycycline respond to treatment (33%).
- 31 people out of 100 who use placebo respond to treatment (31%).
- two more people respond to treatment with doxycycline than with placebo (difference of 2%).
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Physical function
- The effect of doxycycline in physical function is not clinically important.
- People who took doxycycline rated improvement in their physical function to be about 1.4 on a scale of 0 (no disability) to 10 (extreme
disability) after 18 months.
- People who took a placebo rated improvement in their physical function to be about 1.2 on a scale of 0 (no disability) to 10 (extreme
disability) after 18 months.
Another way of saying this is:
- 29 people out of 100 who use doxycycline respond to treatment (29%).
- 26 people out of 100 who use placebo respond to treatment (26%).
- three more people respond to treatment with doxycycline than with placebo (difference of 3%).
Side effects
- 20 people out of 100 who took doxycycline experienced side effects of any type (20%).
- 15 people out of 100 who took a placebo experienced side effects of any type (15%).
- five more people who took doxycycline experienced side effects of any type (absolute difference of 5%).
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B A C K G R O U N D
Description of the condition
Osteoarthritis is a chronic joint disease that involves structural
changes of the joint, leading to pain and functional limitations
(Juni 2006; Zhang 2011). It is characterised by focal areas of loss of
articular cartilage in synovial joints accompanied by subchondral
bone changes, osteophyte formation at the joint margins, thick-
ening of the joint capsule and mild synovitis.
Description of the intervention
Doxycycline is a tetracycline antibiotic that has been shown to
induce inhibition of cartilage matrix metallo-proteinases (MMPs)
and to slow down the progression of structural damage to the af-
fected joint (Smith 1996; Shlopov 1999). Doxycycline was there-
fore suggested as a disease-modifying agent for the treatment of
osteoarthritis.
How the intervention might work
Treatment with oral doxycycline may slow down the rate of joint
space narrowing, which is used as a surrogate measure for cartilage
loss of the knee in people with knee osteoarthritis (Brandt 2005).
Why it is important to do this review
Treatment benefits of putative chondro-protective disease-modify-
ing agents are still controversial. Chondroitin and glucosamine are
other potentially structure-modifying pharmacological substances
that are widely used to reduce the symptoms of osteoarthritis of
the hip or knee. However, some meta-analyses have questioned
their effectiveness because of large heterogeneity between studies
and biases introduced by industry-sponsored, methodologically
weak and small trials (Towheed 2005; Reichenbach 2007; Vlad
2007; Wandel 2010). As a tetracycline antibiotic, doxycycline in-
terferes with various biological pathways and has effects on tissues
other than cartilage (Rubin 2000). Safety concerns about the long-
term use of doxycycline have also been expressed, especially in el-
derly patients with co-morbid conditions (Dieppe 2005). Adverse
events commonly associatedwith the use of tetracycline antibiotics
include nausea, vomiting, epigastric burning, vaginal candidiasis
and photosensitivity (Shapiro1997).
O B J E C T I V E S
We set out to compare doxycycline with placebo or no specific
intervention in people with knee or hip osteoarthritis in terms of
effects on pain, function and safety outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials with a control
group receiving placebo or no intervention.
Types of participants
Studies including at least 75% of participants with osteoarthritis
of the knee or hip confirmed clinically or radiologically, or both.
Types of interventions
Trials investigating doxycycline at any dosage and in any formula-
tion. Eligible control interventions were placebo or no interven-
tion.
Types of outcome measures
Primary outcomes
Main outcomes were pain and function, as currently recom-
mended for osteoarthritis trials (Altman 1996; Pham2004). If data
on more than one pain scale were provided for a trial, we referred
to a previously described hierarchy of pain-related outcomes (Juni
2006; Reichenbach 2007) and extracted data on the pain scale that
was highest on this list. For example, if both the Western Ontario
and McMaster Universities Arthritis Index (WOMAC) pain sub-
scores and pain on walking on a visual analogue scale (VAS) were
reported for a trial, we only extracted and analysed the data on the
outcome pain on walking.
1. Global pain.
2. Pain on walking.
3. WOMAC osteoarthritis index pain subscore.
4. Composite pain scores other than WOMAC.
5. Pain on activities other than walking.
6. Rest pain or pain during the night.
7. WOMAC global algofunctional score.
8. Lequesne osteoarthritis index global score.
9. Other algofunctional scale.
10. Patient’s global assessment.
11. Physician’s global assessment.
If data on more than one function scale were provided for a trial,
we extracted data according to the hierarchy presented below.
1. Global disability score.
2. Walking disability.
3. WOMAC disability subscore.
4. Composite disability scores other than WOMAC.
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5. Disability other than walking.
6. WOMAC global scale.
7. Lequesne osteoarthritis index global score.
8. Other algofunctional scale.
9. Patient’s global assessment.
10. Physician’s global assessment.
If pain or function outcomes were reported at several time points,
we extracted themeasure at the end of the trial or at a maximum of
three months after termination of therapy, whichever came first.
Secondary outcomes
Secondary outcomes were minimum and mean radiographic joint
space width, the number of participants experiencing any adverse
event, participants who withdrew because of adverse events, and
participants experiencing any serious adverse events. We defined
serious adverse events as events resulting in hospitalisation, pro-
longation of hospitalisation, persistent or significant disability,
congenital abnormality/birth defect of offspring, life-threatening
events or death (European Commission 2010).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2008, issue 3), MEDLINE
(1966 to July 2008) and EMBASE (1975 to July 2008) through
the Ovid platform (www.ovid.com), and CINAHL (1937 to July
2008) through EBSCOhost, using truncated variations of prepa-
ration names, including brand names, combined with truncated
variations of terms related to osteoarthritis, all as text words. We
applied a validated methodological filter for controlled clinical tri-
als (Dickersin 1994). The specific search algorithms are displayed
in Appendix 1 for MEDLINE, EMBASE and CINAHL, and in
Appendix 2 for CENTRAL. We updated the search using CEN-
TRAL, MEDLINE and EMBASE up to 16 March 2012.
Searching other sources
We manually searched conference proceedings of the European
League Against Rheumatism (EULAR), the American College
of Rheumatology (ACR), and Osteoarthritis Research Society
International (OARSI), used Science Citation Index to retrieve
reports citing relevant articles, contacted content experts and
trialists, and screened reference lists of all obtained articles,
including related reviews. Finally, we searched several clinical
trial registries (www.clinicaltrials.gov, www.controlled-trials.com,
www.actr.org.au and www.umin.ac.jp/ctr) to identify ongoing tri-
als. The last update of the search was performed on 22 March
2012. OARSI conference proceedings were not searched for the
update as we no longer had access to this database.
Data collection and analysis
We used a generic protocol with instructions for data extraction,
quality assessment and statistical analyses, which was approved by
the editorial board of the Cochrane Musculoskeletal Group. The
same protocol was applied in our previous reviews (Nuesch 2009a;
Nuesch 2009b; Rutjes 2009a; Rutjes 2009b; Reichenbach 2010;
Rutjes 2010).
Selection of studies
Two review authors (originally EN and AR; BdC and AR for the
update) independently evaluated all yielded titles and abstracts for
eligibility. We resolved disagreements by consensus. No language
restrictions were applied. If several reports described the same trial,
we chose themost complete report as themain report and checked
the remaining reports for complementary data on clinical out-
comes, descriptions of study participants or design characteristics.
Data extraction and management
Two review authors (originally EN and AR; BdC and AR for the
update) extracted trial information independently using a stan-
dardised, piloted data extraction form accompanied by a code-
book. We resolved disagreements by discussion or by involvement
of a third review author (SR or PJ).We extracted generic and trade
names of the experimental intervention, the type of control used,
dosage, frequency and duration of treatment, participant charac-
teristics (average age, gender, mean duration of symptoms, type
of joints affected), type of pain- and function-related outcome
extracted, trial design, trial size, duration of follow-up, type and
source of financial support, and publication status from trial re-
ports. Whenever possible, we used results from an intention-to-
treat analysis. If effect sizes could not be calculated, we contacted
the authors for additional data.
Assessment of risk of bias in included studies
Two review authors (originally EN and AR; BdC and AR for the
update) independently assessed the adequacy of randomisation,
blinding and analyses (Juni 2001). We resolved disagreements by
consensus or discussion with a third review author (SR or PJ). We
assessed two components of randomisation: generation of alloca-
tion sequences and concealment of allocation. We considered gen-
eration of sequences adequate if it resulted in an unpredictable al-
location schedule; mechanisms considered adequate included ran-
dom-number tables, computer-generated random numbers, min-
imisation, coin tossing, shuffling cards and drawing lots; trials us-
ing potentially predictable allocation mechanisms, such as alter-
nation or the allocation of participants according to date of birth,
were considered quasi-randomised. We considered concealment
of allocation adequate if the investigators responsible for partic-
ipant inclusion were unable to suspect before allocation which
treatmentwas next;methods considered adequate included central
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randomisation, pharmacy-controlled randomisation using identi-
cal pre-numbered containers, and sequentially numbered, sealed,
opaque envelopes (Nuesch 2009a; Rutjes 2009a). We considered
blinding of the participants adequate if experimental and control
preparations were explicitly described as indistinguishable or if a
double-dummy technique was used (Nuesch 2009a). We consid-
ered blinding of therapists and outcome assessors adequate if it
was explicitly mentioned in the report that they were unaware of
the assigned treatment. However, if pain outcomes were partici-
pant-administered we considered participants to be the outcome
assessors and rated blinding of outcome assessors adequate if par-
ticipants were deemed adequately blinded as described above. We
considered analyses adequate if all randomised participants were
included in the analysis (intention-to-treat principle). We consid-
ered trials to have a high risk of selective reporting bias if we iden-
tified one or more outcome measures in published reports, proto-
cols or trial registries for which results were not reported. Finally,
we used GRADE to describe the quality of the overall body of
evidence (Guyatt 2008; Higgins 2011), defined as the extent of
confidence in the estimated treatment benefits and harms.
Data synthesis
We expressed continuous outcomes as effect sizes in standard de-
viation units, with the differences in mean values at the end of
follow-up across treatment groups divided by the pooled standard
deviation. If differences in mean values at the end of the treatment
were unavailable, we used differences in mean changes. If some
of the required data were unavailable, we used approximations as
previously described (Reichenbach 2007). An effect size of -0.20
standard deviation units can be considered a small difference be-
tween experimental and control groups, an effect size of -0.50 a
moderate difference, and -0.80 a large difference (Cohen 1988;
Juni 2006). We expressed binary outcomes as risk ratios (RR).
We pooled treatment effect estimates across trials using a standard
inverse-variance random-effects model, which fully accounted for
between-study variance.We quantified between-study variance us-
ing the I2 statistic (Higgins 2003), which describes the percentage
of variation across trials that is attributable to heterogeneity rather
than to chance, and the corresponding Chi2 test. I2 values of 25%,
50% and 75% may be interpreted as low, moderate and high be-
tween-trial heterogeneity, although the size of trials included in
the meta-analysis should be taken into consideration for proper
interpretation (Rucker 2008).
We converted effect sizes of pain intensity and function to odds
ratios (ORs) (Chinn 2000; da Costa 2012) as the first step to de-
rive numbers needed to treat to cause one additional beneficial
outcome (NNTB) or treatment response on pain or function as
compared with placebo, and numbers needed to treat to cause one
additional harmful outcome (NNTH) (as was done for the ’Sum-
mary of findings table’). We defined treatment response as a 50%
improvement in scores (Clegg 2006). With a median standardised
pain intensity at baseline of 2.4 standard deviation units, observed
in large osteoarthritis trials (Nuesch 2009c), this corresponds to
an average decrease in scores of 1.2 standard deviation units. Based
on the median standardised decrease in pain scores of 0.72 stan-
dard deviation units (Nuesch 2009c), we calculated that a median
of 31% of participants in the placebo group would achieve an
improvement of pain scores of 50% or more. This percentage was
used as the control group response rate to derive from ORs the
response rate in the experimental group. NNTBs for treatment
response on pain were derived by calculating the inverse of the
difference between experimental and control group response rates.
Based on the median standardised WOMAC function score at
baseline of 2.7 standard deviation units and the median standard-
ised decrease in function scores of 0.58 standard deviation units
(Nuesch 2009c), 26% of participants in the placebo group would
achieve a reduction in function of 50% or more. Again, this per-
centage was used as the control group response rate to derive from
ORs the response rate in the experimental group, which were then
used to calculate NNTBs for treatment response on function. The
median risks of 150 participants with adverse events per 1000 pa-
tient-years, four participants with serious adverse events per 1000
patient-years, and 17 drop-outs due to adverse events per 1000
patient-years as observed in placebo groups in large osteoarthritis
trials (Nuesch 2009c) were used to calculate NNTHs for safety
outcomes. We performed analyses in RevMan version 5 (RevMan
2011). All P values were two-sided.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
We retrieved 288 potentially relevant reports from our electronic
searches (Figure 1).We excluded a randomised placebo-controlled
trial of doxycycline in seronegative arthritis (Smieja 2001) and an
animal study that assessed the effects of oral doxycycline in dogs
(Brandt 1995). Twelve reports, describing two randomised con-
trolled trials, met our inclusion criteria (Brandt 2005; Snijders
2011). The trial by Snijders 2011 was identified during the update
of our literature search. We did not find any additional completed
trials in conference proceedings, neither did we identify relevant
ongoing trials in trial registers. The trial by Brandt et al. (Brandt
2005) was a multicentre, placebo-controlled trial in 431 obese
women with radiologically confirmed osteoarthritis of the knee.
After a single-blind placebo run-in of four weeks’ duration, which
was designed to allow the exclusion of participants unlikely to be
compliant with trial procedures, participants were randomly allo-
cated to receive doxycycline 100 mg or placebo twice a day for 30
months. Participants were permitted to take any pain medication
throughout the trial. The trial by Snijders et al. (Snijders 2011) was
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a single-centre, placebo-controlled trial in 232 participants with
radiologically confirmed osteoarthritis of the knee and a score of
≥ 20 in the WOMAC pain subscale ranging from 0 to 100. Par-
ticipants were randomly allocated to receive doxycycline 100 mg
or placebo twice a day for 24 weeks. Participants were permitted
to take pain medication throughout the trial, but opioids other
than tramadol were not allowed.
Figure 1. Flow chart.
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Risk of bias in included studies
An overview of the methodological characteristics of the included
trial is presented in Figure 2 and Figure 3. The trial by Brandt et
al. (Brandt 2005) was described as randomised in blocks of six,
althoughmechanisms to generate blocks of random sequences and
methods used to conceal allocation to treatments were not spec-
ified. The trial was reported as double blind after a single-blind
run-in period. We deemed blinding of participants adequate in
view of the use of a matching placebo. Participants were explic-
itly described as blinded, whereas blinding of treating physicians
was not explicitly described. Analyses of clinical outcomes, such
as pain and function, were based on 307 participants who com-
pleted the 30-month treatment period as mandated in the pro-
tocol (Brandt 2005). Analyses of radiological outcomes included
all 361 participants who returned for their radiographic follow-
up irrespective of whether they discontinued the study drug. Sa-
fety analyses included all 431 randomised participants according
to the intention-to-treat principle. The primary outcome of the
trial was joint space narrowing on the semiflexed AP view in the
tibiofemoral joint (Buckland-Wright 1995). Measurements were
done manually, according to the method of Lequesne (Lequesne
1995), using the points of a screw-adjustable compass and a grad-
uated magnifying lens. Measurements were made by an observer
who was blinded to the treatment group assignment of the subject.
The intra- and inter-reader reproducibilities of repeated measure-
ments of joint space width in a random sample of 30 radiographs
(on which all identifying information was masked) were excellent
(intraclass correlation coefficients of 0.99 and 0.96, respectively).
Assessors determining the joint space width were not blinded to
the sequence of the radiographs. No sample size calculation was
described. The trial was supported in part by the National Insti-
tutes of Health (NIH); no commercial funding was reported.
Figure 2. Methodological characteristics and source of funding of the included trial. (+) indicates low risk of
bias, (?) unclear and (-) a high risk of bias on a specific item.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
In the trial by Snijders et al. (Snijders 2011), participants were ran-
domised using a computer-generated randomisation list stratified
by pain intensity (< 60 vs. ≥ 60 on the WOMAC pain subscale).
Coded drug packs, organised by an independent pharmacist who
centrally stored the randomisation list, were used for concealment
of allocation. The treating physician had no access to the randomi-
sation schedule. The trial was reported as triple-blind, with par-
ticipants, physicians and outcome assessors explicitly described to
be blinded. We considered blinding of participants and physicians
to be adequate given matching placebo and adequate concealment
of allocation. We considered blinding of outcome assessors ade-
quate because all outcomes were assessed either by the participant
or physician, who both were deemed adequately blinded. Anal-
yses of pain and function outcomes were based on 218 and 210
participants, respectively, who had non-missing data at the end of
the 24 week treatment period. Safety analyses were based on all
232 participants randomised according to the intention-to-treat
principle. The primary outcome of the trial was clinical response
at the end of treatment as defined by the OMERACT-OARSI
responder criteria (Pham 2004). It remained unclear whether the
trial was supported by commercial funding.
For the effectiveness outcomes, we classified the quality of the ev-
idence (Guyatt 2008) as moderate, because two large-scale trials
of moderate quality were available, with one of the trials lacking a
description of concealment of allocation and only including obese
women (Brandt 2005), and both trials lacking intention-to-treat-
analysis (see ’Summary of findings for the main comparison’). For
any adverse event, serious adverse events, and withdrawals due to
adverse events outcomes, we classified the quality of the evidence
(Guyatt 2008) as low because estimates were imprecise with con-
fidence intervals including negligible and appreciable effects, and
because one of the trials lacked a description of concealment of
allocation and only included obese women (Brandt 2005) (see
’Summary of findings for the main comparison’).
Effects of interventions
See: Summary of findings for the main comparison
In the trial by Brandt et al. (Brandt 2005) knee pain was measured
after a 15.2-m (50-feet) walk on a 10-cm VAS, and in the trial
by Snijders et al. (Snijders 2011) pain was measured using the
WOMAC pain subscale. The analyses suggested that there is no
difference between doxycycline and placebo in pain relief. The
effect size was -0.05 (95%confidence interval (CI) -0.22 to 0.13; P
= 0.60; Analysis 1.1), which correspondswith a difference between
doxycycline and placebo of -0.1 cm on a 10-cm VAS, favouring
doxycycline. Visual inspection of the forest plot and the I2 estimate
indicated no relevant heterogeneity of treatment effect estimates
across the two trials (I2 = 0%).
The WOMAC function subscale was used to measure function in
both trials. The analyses suggested an effect size of -0.07 (95%CI -
0.25 to 0.10; P = 0.39; Analysis 1.2), corresponding to a difference
between doxycycline and control of -0.2 (95% CI -0.5 to 0.2) on
the WOMAC disability subscale with a range of 0 to 10. Visual
inspection of the forest plot and the I2 estimate again did not
indicate any relevant difference between trial heterogeneity (I2 =
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0%).
The difference in changes in minimum joint space narrowing was
in favour of doxycycline (-0.15 mm; 95% CI -0.28 to -0.02 mm;
P = 0.03; Analysis 1.3), which corresponds to a small effect size of
-0.23 standard deviation units (95% CI -0.44 to -0.02).
Regarding safety, participants were more than twice as likely to
withdraw due to adverse events in the doxycycline group com-
pared to the placebo group (RR 2.28; 95% CI 1.06 to 4.90; P =
0.04; I2 = 55%; Analysis 1.4). Data for the number of participants
experiencing any type of adverse event was only available for the
trial of Snijders et al. (Snijders 2011; data provided in personal
communication). Compared to the placebo group, participants
in the doxycycline group were more likely to experience any type
of adverse event (RR 1.36; 95% CI 1.08 to 1.72; Analysis 1.5).
For the trial of Brandt et al. (Brandt 2005), data on serious ad-
verse events were provided by investigators in personal communi-
cations. In the combined analysis on serious adverse events, there
was no evidence that doxycycline was unsafe, but the estimate was
imprecise (RR 1.07; 95% CI 0.68 to 1.68; P = 0.77; I2 = 0%;
Analysis 1.6). In both trials, there were no fatal events and none
of the serious adverse events were deemed to be related to doxy-
cycline (Brandt 2005; Snijders 2011).
D I S C U S S I O N
Summary of main results
In this update, we found that the symptomatic benefit of doxy-
cycline in people with osteoarthritis of the knee was minimal to
non-existent. The small benefit in terms of joint space narrowing
was of questionable clinical relevance. The increased risks of ex-
periencing adverse events, and dropping out due to adverse events
in the doxycycline group compared to placebo indicates that this
benefit is outweighed by safety problems.
Quality of the evidence
The evidence is based on two large randomised trials (Brandt
2005; Snijders 2011). The trial of Brandt et al. included only obese
women with mild to moderate osteoarthritis of the knee and was
designed to detect differences in joint space narrowing rather than
differences in clinical outcomes (Brandt 2005). No threshold for
the level of knee painwas used for inclusion and the average level of
knee painwas low at baseline, leaving little room for improvement.
Radiological and clinical outcomes correlate poorly in people with
osteoarthritis and it is not surprising that effects of doxycycline
differed for these outcomes. Joint space width in millimetres eval-
uated on radiographs is currently considered to be the preferred
technique to evaluate structural progression in osteoarthritis, and
is required by the regulatory agencies (Hellio 2009). The use of
semiflexed radiographs instead of anteroposterior (AP) views im-
proves detection of tibiofemoral joint space narrowing, especially
in early osteoarthritis (Merle-Vincent 2007). However, there is
a debate about how to define relevant radiographic progression,
and a published OARSI-OMERACT initiative recommends di-
chotomising the continuous variable of joint space narrowing to
distinguish between progressors and non-progressors, based on the
absolute change in joint space width over a pre-defined thresh-
old (Ornetti 2009). Mazzuca et al. reported that doxycycline did
not differ from placebo in the frequency of relevant joint space
loss using a range of different cut-offs to distinguish between the
presence or absence of relevant joint space loss (≥ 0.5 mm, ≥ 1.0
mm, ≥ 20%, or ≥ 50% of joint space width at baseline; Mazzuca
2006). No evidence for the effect of doxycycline on joint space
narrowing is available for people representing a broader spectrum
of osteoarthritis, including males, people with hip osteoarthritis
and non-obese people. In the trial by Snijders et al., participants
were included regardless of gender or body weight (Snijders 2011).
As opposed to the trial by Brandt et al., this trial had symptom
severity as primary outcome measure, requiring a minimum pain
severity for inclusion in the trial. Although participants presented
a moderate level of knee pain at baseline, on average 49 on a scale
from 0 to 100, no effect of doxycycline compared to placebo was
observed on pain or disability, confirming the results of the earlier
conducted trial by Brandt et al. (Brandt 2005).
According to our ’Risk of bias’ assessment, both trials made some
suboptimal design choices. Brandt 2005 was potentially biased: it
remainedunclearwhether sequence generation and allocation con-
cealment were adequate and a high number of participants were
excluded from analyses, which may have resulted in some overes-
timation of benefits (Nuesch 2009c). In addition, there are dis-
crepancies in definitions of the primary outcome between the trial
protocol (ClinicalTrials.gov Identifier: NCT00000403) and the
published trial report (Brandt 2005). The single primary outcome
of this trial as originally specified in the protocol was joint space
narrowing in the tibiofemoral compartment of the contralateral
knee with little structural changes, whereas in the published trial
report there were two primary outcomes, joint space narrowing
in index and in contralateral knee. Although doxycycline slightly
decreased joint space narrowing in the index knee, it had no effect
in the contralateral knee. In view of the change in the primary out-
come definition and the lack of effect found for the original pri-
mary outcome, we considered the effects of doxycycline on joint
space narrowing in the trial by Brandt 2005 to be unclear. The
trial by Snijders 2011 is considerably less prone to bias. Blinding
of participants, clinicians and outcome assessors was adequate and
adequate methods were used to conceal treatment allocation.
Potential biases in the review process
We based our review on a broad literature search and it seems
unlikely that we missed relevant trials (Egger 2003). Two review
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authors performed selection of trials and data extraction indepen-
dently and in duplicate to minimise bias and transcription errors
(Egger 2001; Gøtzsche 2007). As with any systematic review, our
study is limited by the quality of the available evidence. As indi-
cated above, two trials were available, with one of the trials (Brandt
2005) having some methodological shortcomings. However, both
trials were large and consistently showed clinical null effects. The
biases discussed would on average result in some overestimation
of treatment effect and, even if real, would not change any of our
conclusions.
Agreements and disagreements with other
studies or reviews
Doxycycline may reduce the progression of cartilage degenera-
tion in canine osteoarthritis through inhibition of cartilageMMPs
(Yu 1992; Brandt 1995). Similar results were obtained in guinea
pigs (Greenwald 1994) and rabbits (Golub 1993). In a canine
osteoarthritis model, doxycycline reduced disease progression (Yu
1992). This notion supports the observed reduction in joint space
narrowing in the randomised trial in humans (Brandt 2005).
When studied inpeoplewith chronic seronegative arthritis (Smieja
2001), doxycycline had no effect on pain reduction or function
improvement compared to placebo after three months of treat-
ment. The trials included in our review included participants with
non-inflammatory symptomatic osteoarthritis and used a longer
treatment duration but results were similar (Brandt 2005; Snijders
2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The symptomatic benefit of doxycycline is minimal to non-exis-
tent, while the small benefit in terms of joint space narrowing is
of questionable clinical relevance and outweighed by safety prob-
lems.
Implications for research
The available evidence of the effectiveness of doxycycline is based
on two randomised trials. Despite some methodological short-
comings, and despite the sampling of only obese women in Brandt
2005, it seems unlikely that future trials would detect a clinically
relevant benefit of doxycycline. In addition, the number of 663
patients included in our meta-analysis exceeds the optimal infor-
mation size (Pogue 1997; Guyatt 2011) of 342 patients, which
was defined as the size of a single trial with adequate power of
80% to detect a minimally important difference between groups
of 0.37 standard deviation units (Rutjes 2012) for pain, function
or joint space width at an alpha level of 0.01. Therefore, we see
no need for additional trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brandt 2005
Methods Randomised controlled trial with 2 parallel groups
Randomisation stratified by centre
Trial duration: 30 months
Multicentre trial including 6 centres
No power calculation reported
Participants 431 participants with radiologically confirmed knee osteoarthritis were randomised
Number of females: 431 (100%)
Average age: 54.9 years
Average BMI: 36.7 kg/m2
Severity of knee osteoarthritis: 59% with Kellgren/Lawrence grade 2 and 41% with
Kellgren/Lawrence grade 3
Duration of knee complaints: not reported
Interventions Experimental intervention: doxycycline, 100 mg twice daily
Control intervention: placebo, twice daily
Treatment duration: 30 months
Analgesics other than study drugs allowed and intake was similar between groups
Outcomes Extracted pain outcome: 15.2 m (50-feet) walking pain after 30 months
Extracted function outcome: WOMAC disability subscore after 30 months
Primary outcome: joint space narrowing in the tibiofemoral compartment of the con-
tralateral knee
Notes ClinicalTrials.gov Identifier: NCT00000403
The trial was supported by the a non-profit organisation (NIH grants R01-AR-43348,
P60-AR-20582 and R01-AR-44370). It is unclear whether this trial received funding
from a commercial body
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects (...) were randomly as-
signed”
Comment: no mention of the mechanism
used for sequence generation
Allocation concealment (selection bias) Unclear risk Quote: “Patients were allocated randomly
to treatment groups in blocks of 6”
Comment: no mention of concealment of
allocation
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Brandt 2005 (Continued)
Blinding of patients described? Low risk Quote: “matched placebo”
Comment: indistinguishable interventions
and the description of a double-blind phase
implies blinding of participants
Blinding of physicians? Low risk Comment: clearly distinguished between
single blind run-in period and double-
blind phase. Blinding of physicians proba-
ble
Blinding of outcome assessors? Low risk Comment: depending on the outcome,
participants or physicians were the asses-
sors, both of which were blinded
Intention-to-treat analysis?
All outcomes
High risk Pain outcome: 69 of 218 participants
(32%) excluded in experimental group and
55 of 213 participants (26%) excluded in
control group
Function outcome: 69 of 218 participants
(32%) excluded in experimental group and
55 of 213 participants (26%) excluded in
control group
Free of selective reporting? High risk Comment: there were 2 instruments (SF-
36 and Pain at rest) assessed during the trial
but that results were not available in any
of the trial reports. These instruments were
identified in the trial registration and amul-
tiple trial report (Mazzuca et al. 2004). Trial
registration occurred after trial main report
(Brandt et al. 2005) was published
Funding by commercial body avoided? Unclear risk No information provided regarding fund-
ing from commercial body
Snijders 2011
Methods Randomised controlled trial with 2 parallel groups, using an allocation ratio of 1:1
Randomisation stratified by pain intensity at screening visit, using stratified block ran-
domisation
Trial duration: 6.1 months
Single-centre trial
Power calculation reported
Participants 232 participants with radiologically confirmed knee osteoarthritis were randomised
Number of females: 154 (66%)
Average age: 59 years
Average BMI: 30 kg/m2
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Snijders 2011 (Continued)
Severity of knee osteoarthritis: 65% with Kellgren/Lawrence grade 2 and 35% with
Kellgren/Lawrence grade 3
Duration of knee complaints: 6 years
Interventions Experimental intervention: doxycycline, 100 mg twice daily
Control intervention: placebo twice daily
Treatment duration: 5.6 months (24 weeks)
Analgesics other than study drugs allowed up to 48 hours or four times the drug’s half-
life, or both, before study visits for outcome assessment. Opioids other than tramadol
were not allowed. Analgesics intake was similar between groups
Outcomes Extracted pain outcome: WOMAC pain subscore after 5.6 months
Extracted function outcome: WOMAC disability subscore after 5.6 months
Primary outcome: proportion responders according to theOMERACT-OARSI response
criteria
Notes Dutch Trial Register identifier (www.trialregister.nl): NTR1111
All statistical analyses were performed blinded for treatment allocation
It is unclear whether this trial received funding from a commercial body
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “an independent pharmacist used
a computer-generated, blinded randomi-
sation list to assign patients randomly to
doxycycline or placebo”
Comment: randomisation list was com-
puter generated
Allocation concealment (selection bias) Low risk Quote: “an independent pharmacist used
a computer-generated, blinded randomi-
sation list to assign patients randomly to
doxycycline or placebo” and “allocation
data were stored at the hospital pharmacy
in sealed envelopes that could be opened in
the case of medical need”
Comment: allocation conducted by in-
dependent pharmacist using blinded ran-
domisation list, the list was stored centrally,
the treating physician had no access do the
randomisation list
Blinding of patients described? Low risk Quote: “the allocation was blinded for pa-
tient and study physician using placebo
medication capsules, blue and white, with
the same appearance as verum” and “triple-
blind, placebo controlled trial”
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Snijders 2011 (Continued)
Comment: indistinguishable inter-
ventions, the description of a triple-blind
phase implies blinding of participants, par-
ticipants explicitly reported as blinded
Blinding of physicians? Low risk Quote: “the allocation was blinded for pa-
tient and study physician using placebo
medication capsules, blue and white, with
the same appearance as verum” and “triple-
blind, placebo controlled trial”
Comment: indistinguish-
able interventions, study physician explic-
itly reported as blinded, and trial reported
as triple-blinded
Blinding of outcome assessors? Low risk Comment: depending on the outcome,
participants or physicians were the asses-
sors, both of which were blinded
Intention-to-treat analysis?
All outcomes
High risk Pain outcome: 8 of 116 participants (7%)
excluded in experimental group and 6 of
116 participants (5%) excluded in the con-
trol group
Function outcome: 13 of 116 participants
(11%) excluded in experimental group and
9 of 116 participants (8%) excluded in con-
trol group
The authors considered lost to follow-up
to be “missing not at random” owing to se-
lective lost to follow-up in the doxycycline
trial arm, owing to adverse events
Free of selective reporting? Low risk Comment: all outcomes mentioned in the
methods section are addressed in the re-
sults section, no discrepancies were de-
tected between entrees for NTR1111 at
www.trialregister.nl, the full-text publica-
tion, and the published abstract in Annals
of the Rheumatic Diseases
Funding by commercial body avoided? Unclear risk Quote: “the authors thank Dr BJF van den
Bemt for study medication supply”
Comment: no information provided re-
garding financial support
BMI: body mass index; SF-36: 36-item short form; WOMAC: Western Ontario and McMaster Universities Arthritis Index.
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Characteristics of excluded studies [ordered by year of study]
Study Reason for exclusion
Brandt 1995 Animal study
Smieja 2001 No participants in osteoarthritis
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D A T A A N D A N A L Y S E S
Comparison 1. Doxycycline versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 2 524 Std. Mean Difference (Random, 95% CI) -0.05 [-0.22, 0.13]
2 Physical function 2 517 Std. Mean Difference (Random, 95% CI) -0.07 [-0.25, 0.10]
3 Minimum joint space width 1 361 Mean Difference (IV, Random, 95% CI) -0.15 [-0.28, -0.02]
4 Number of patients withdrawn
due to adverse events
2 663 Risk Ratio (IV, Random, 95% CI) 2.28 [1.06, 4.90]
5 Number of patients experiencing
any adverse event
1 232 Risk Ratio (IV, Random, 95% CI) 1.36 [1.08, 1.72]
6 Number of patients experiencing
any serious adverse events
2 663 Risk Ratio (IV, Random, 95% CI) 1.07 [0.68, 1.68]
Analysis 1.1. Comparison 1 Doxycycline versus placebo, Outcome 1 Pain.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 1 Pain
Study or subgroup Experimental Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Brandt 2005 148 158 -0.078 (0.114) 58.7 % -0.08 [ -0.30, 0.15 ]
Snijders 2011 108 110 0 (0.136) 41.3 % 0.0 [ -0.27, 0.27 ]
Total (95% CI) 100.0 % -0.05 [ -0.22, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours experimental Favours control
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Analysis 1.2. Comparison 1 Doxycycline versus placebo, Outcome 2 Physical function.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 2 Physical function
Study or subgroup Experimental Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Brandt 2005 149 158 -0.089 (0.114) 59.4 % -0.09 [ -0.31, 0.13 ]
Snijders 2011 103 107 -0.054 (0.138) 40.6 % -0.05 [ -0.32, 0.22 ]
Total (95% CI) 100.0 % -0.07 [ -0.25, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours experimental Favours control
Analysis 1.3. Comparison 1 Doxycycline versus placebo, Outcome 3 Minimum joint space width.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 3 Minimum joint space width
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mm] N Mean(SD)[mm] IV,Random,95% CI IV,Random,95% CI
Brandt 2005 181 0.3 (0.6) 180 0.45 (0.7) 100.0 % -0.15 [ -0.28, -0.02 ]
Total (95% CI) 181 180 100.0 % -0.15 [ -0.28, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours doxycycline Favours placebo
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Analysis 1.4. Comparison 1 Doxycycline versus placebo, Outcome 4 Number of patients withdrawn due to
adverse events.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 4 Number of patients withdrawn due to adverse events
Study or subgroup Doxycycline Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Brandt 2005 38/218 22/213 63.1 % 1.69 [ 1.03, 2.75 ]
Snijders 2011 19/116 5/116 36.9 % 3.80 [ 1.47, 9.83 ]
Total (95% CI) 334 329 100.0 % 2.28 [ 1.06, 4.90 ]
Total events: 57 (Doxycycline), 27 (Placebo)
Heterogeneity: Tau2 = 0.18; Chi2 = 2.21, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours doxcycline Favours placebo
Analysis 1.5. Comparison 1 Doxycycline versus placebo, Outcome 5 Number of patients experiencing any
adverse event.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 5 Number of patients experiencing any adverse event
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Snijders 2011 75/116 55/116 100.0 % 1.36 [ 1.08, 1.72 ]
Total (95% CI) 116 116 100.0 % 1.36 [ 1.08, 1.72 ]
Total events: 75 (Experimental), 55 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0094)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Doxycycline versus placebo, Outcome 6 Number of patients experiencing any
serious adverse events.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 6 Number of patients experiencing any serious adverse events
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Brandt 2005 (1) 31/218 29/213 93.4 % 1.04 [ 0.65, 1.67 ]
Snijders 2011 3/116 2/116 6.6 % 1.50 [ 0.26, 8.81 ]
Total (95% CI) 334 329 100.0 % 1.07 [ 0.68, 1.68 ]
Total events: 34 (Experimental), 31 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours doxycycline Favours placebo
(1) Unpublished data provided by investigators in personal communication.
A P P E N D I C E S
Appendix 1. MEDLINE, EMBASE and CINAHL search strategy
OVID MEDLINE OVID EMBASE CINAHL through EBSCOhost
Search terms for design
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trial.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single blind method.sh.
7. clinical trial.pt.
8. exp clinical trial/
9. (clin$ adj25 trial$).ti,ab.
10. ((singl$ or doubl$ or trebl$ or tripl$)
adj25 (blind$ or mask$)).ti,ab.
11. placebos.sh.
12. placebo$.ti,ab.
Search terms for design
1. randomized controlled trial.sh.
2. randomization.sh.
3. double blind procedure.sh.
4. single blind procedure.sh.
5. exp clinical trials/
6. (clin$ adj25 trial$).ti,ab.
7. ((singl$ or doubl$ or trebl$ or tripl$)
adj25 (blind$ or mask$)).ti,ab.
8. placebo.sh.
9. placebo$.ti,ab.
10. random$.ti,ab.
11. methodology.sh.
12. comparative study.sh.
Search terms for design
1. (MH “Clinical Trials+”)
2. (MH “Random Assignment”)
3. (MH “Double-Blind Studies”) or (MH
“Single-Blind Studies”)
4. TX (clin$ n25 trial$)
5. TX (sing$ n25 blind$)
6. TX (sing$ n25 mask$)
7. TX (doubl$ n25 blind$)
8. TX (doubl$ n25 mask$)
9. TX (trebl$ n25 blind$)
10. TX (trebl$ n25 mask$)
11. TX (tripl$ n25 blind$)
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(Continued)
13. random$.ti,ab.
14. research design.sh.
15. comparative study.sh.
16. exp evaluation studies/
17. follow up studies.sh.
18. prospective studies.sh.
19. (control$ or prospectiv$ or volunteer$)
.ti,ab.
13. exp evaluation studies/
14. follow up.sh.
15. prospective study.sh.
16. (control$ or prospectiv$ or volunteer$)
.ti,ab.
12. TX (tripl$ n25 mask$)
13. (MH “Placebos”)
14. TX placebo$
15. TX random$
16. (MH “Study Design+”)
17. (MH “Comparative Studies”)
18. (MH “Evaluation Research”)
19. (MH “Prospective Studies+”)
20. TX (control$ or prospectiv$ or volun-
teer$)
21. S1 or S2 or (…….) or S20
Search terms for Osteoarthritis
20. exp osteoarthritis/
21. osteoarthriti$.ti,ab,sh.
22. osteoarthro$.ti,ab,sh.
23. gonarthriti$.ti,ab,sh.
24. gonarthro$.ti,ab,sh.
25. coxarthriti$.ti,ab,sh.
26. coxarthro$.ti,ab,sh.
27. arthros$.ti,ab.
28. arthrot$.ti,ab.
29. ((knee$ or hip$ or joint$) adj3 (pain$
or ach$ or discomfort$)).ti,ab.
30. ((knee$ or hip$ or joint$) adj3 stiff$).
ti,ab.
Search terms for Osteoarthritis
17. exp osteoarthritis/
18. osteoarthriti$.ti,ab,sh.
19. osteoarthro$.ti,ab,sh.
20. gonarthriti$.ti,ab,sh.
21. gonarthro$.ti,ab,sh.
22. coxarthriti$.ti,ab,sh.
23. coxarthro$.ti,ab,sh.
24. arthros$.ti,ab.
25. arthrot$.ti,ab.
26. ((knee$ or hip$ or joint$) adj3 (pain$
or ach$ or discomfort$)).ti,ab.
27. ((knee$ or hip$ or joint$) adj3 stiff$).
ti,ab.
Search terms for Osteoarthritis
22. osteoarthriti$
23. (MH “Osteoarthritis”)
24. TX osteoarthro$
25. TX gonarthriti$
26. TX gonarthro$
27. TX coxarthriti$
28. TX coxarthro$
29. TX arthros$
30. TX arthrot$
31. TX knee$ n3 pain$
32. TX hip$ n3 pain$
33. TX joint$ n3 pain$
34. TX knee$ n3 ach$
35. TX hip$ n3 ach$
36. TX joint$ n3 ach$
37. TX knee$ n3 discomfort$
38. TX hip$ n3 discomfort$
39. TX joint$ n3 discomfort$
40. TX knee$ n3 stiff$
41. TX hip$ n3 stiff$
42. TX joint$ n3 stiff$
43. S22 or S23 or S24….or S42
Search terms for Doxycycline
31. exp doxycycline/
32. doxycycline.tw.
33. deoxyoxytetracycline.tw.
34. hydramycin.tw.
35. vibramycin.tw.
36. vibravenos.tw.
37. oracea.tw.
38. adoxa.tw.
39. doryx.tw.
40. doxy$.tw.
41. monodox$.tw.
42. periostat.tw.
43. atridox.tw.
Search terms for Doxycycline
28. exp doxycycline/
29. doxycycline.tw.
30. deoxyoxytetracycline.tw.
31. hydramycin.tw.
32. vibramycin.tw.
33. vibravenos.tw.
34. oracea.tw.
35. adoxa.tw.
36. doryx.tw.
37. doxy$.tw.
38. monodox$.tw.
39. periostat.tw.
Search terms for Doxycycline
44. (MH “ Doxycycline ”)
45. TX doxycycline
46. TX deoxyoxytetracycline
47. TX hydramycin
48. TX vibramycin
49. TX vibravenos
50. TX oracea
51. TX adoxa
52. TX doryx
53. TX doxy$
54. TX monodox$
55. TX periostat
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(Continued)
44. vibrox$.tw. 40. atridox.tw.
41. vibrox$.tw.
56. TX atridox
57. TX vibrox$
58. S44 or S45 or …. S57
Combining terms
45. or/1-19
46. or/20-30
47. or/31-44
48. and/45-47
49. animal/
50. animal/ and human/
51. 49 not 50
52. 48 not 51
53. remove duplicates from 52
Combining terms
42. or/1-16
43. or/17-27
44. or/28-41
45. and/42-44
46. animal/
47. animal/ and human/
48. 46 not 47
49. 45 not 48
50. remove duplicates from 49
Combining terms
59. S21 and S43 and S58
Appendix 2. CENTRAL search strategy
CENTRAL
Search terms for osteoarthritis
#1. MeSH descriptor Osteoarthritis explode all trees
#2. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro*
OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR
((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discomfort*))
OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials
Search terms for doxycycline
#3. MeSH descriptor Doxycycline explode all trees
#4. doxycycline in Clinical Trials
#5. deoxyoxytetracycline in Clinical Trials
#6. hydramycin in Clinical Trials
#7. vibramycin in Clinical Trials
#8. vibravenos in Clinical Trials
#9. oracea in Clinical Trials
#10. adoxa in Clinical Trials
#11. doryx in Clinical Trials
#12. doxy* in Clinical Trials
#13. monodox* in Clinical Trials
#14. periostat in Clinical Trials
#15. atridox in Clinical Trials
#16. vibrox* in Clinical Trials
Combining terms
#17. (#1 OR #2)
#18. (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)
#19. (#17 AND #18) in Clinical Trials
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WH A T ’ S N E W
Last assessed as up-to-date: 16 March 2012.
Date Event Description
25 June 2012 New citation required but conclusions have not changed Change in authorship
20 March 2012 New search has been performed Search updated, one new trial included
H I S T O R Y
Protocol first published: Issue 3, 2008
Review first published: Issue 4, 2009
Date Event Description
1 May 2008 Amended CMSG ID C118-R
C O N T R I B U T I O N S O F A U T H O R S
Protocol completion: Nüesch, Rutjes, Reichenbach, Jüni
Acquisition of data: da Costa, Nüesch, Rutjes
Analysis and interpretation of data: da Costa, Nüesch, Reichenbach, Jüni, Rutjes
Manuscript preparation: da Costa, Nüesch, Reichenbach, Jüni, Rutjes
Statistical analysis. da Costa, Nüesch, Rutjes
D E C L A R A T I O N S O F I N T E R E S T
None.
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S O U R C E S O F S U P P O R T
Internal sources
• Institute of Social and Preventive Medicine, University or Bern, Switzerland.
Intramural grants
External sources
• Swiss National Science Foundation, Switzerland.
National Research Program 53 on musculoskeletal health (grant numbers 4053-40-104762/3 and 3200-066378)
• ARCO Foundation, Switzerland.
Research program on knee and hip osteoarthritis
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Because only two studies were included in our review, we did not perform stratified analyses or funnel plot evaluation to investigate
whether potential variation between trials could be explained by biases affecting individual trials or by publication bias. We did not
include the electronic database CINAHL in our search update since, in our previous search, this database did not identify any additional
hits. Finally, we did not include the OARSI database in our search update as we no longer had access to this database.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antirheumatic Agents [∗therapeutic use]; Doxycycline [∗therapeutic use]; Osteoarthritis, Hip [∗drug therapy]; Osteoarthritis, Knee
[∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans
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